IL6 and Cowden syndrome 1: Immunotherapy which activates T cells by binding to both CD19+ and CD3+ T cells results in iatrogenic CS and the pathological cascade has been successfully inhibited by using anti-IL-6 antibody therapy, which further affirms the role of IL-6 [97].